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Abstract
BK virus (BKV) is a human polyomavirus with a seroprevalence of 60–80 % in the general population. In renal
transplant patients, it is known to cause renal failure, ureteric stenosis and hemorrhagic cystitis. In bone marrow
transplant patients, it is evident that BKV can also cause hemorrhagic cystitis along with BK virus nephropathy
(BKVN) in the native kidneys, with subsequent renal failure. However, little is known about BVKN in non-transplanted
immune-compromised patients, such as systemic lupus erythematosus (SLE) who may have underlying nephritis
and have a compromised immune system due to therapy and/or systemic illness. Thus, this article will focus on the
clinical aspects of BKV and its association in patients with SLE.
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Introduction
BK virus (BKV) is a ubiquitous polyoma virus that is
often acquired during early childhood. It lies dormant in
the genito-urinary tract, but can become reactivated in
certain immunocompromised disease states. The micro-
environment needed for BKV replication includes an
interplay between the viral characteristics, host’s altered or
impaired immune system, inflammation and/or intrinsic
kidney damage. BKV replication is observed after renal
transplantation, and can lead to loss of the renal allograft
in half of the cases. BKV replication is also observed in
other solid-organ transplant recipients, bone marrow
transplant recipients, human immunodeficiency virus
(HIV) patients, pregnant women, multiple sclerosis and
other immunocompromised patients. The use of immuno-
suppressive drugs, including biologics, strongly impacts
the host’s immune system which increases the risk for cer-
tain opportunistic bacterial, viral, and fungal infections. In
some particular groups of non-transplanted immune-
compromised patients, such as systemic lupus erythema-
tosus (SLE) who have a higher degree of renal involvement
and/or systemic illness, the impact of BK virus replication
is not known. Thus, this review article will focus on the
describing the clinical aspects of BKV and a review of the




BK virus is a human polyomavirus belonging to the family
Papovaviridae. The other member of the Papovaviridae
family is the Papillomavirus genus. The polyoma genus
was named after the murine polyoma virus that caused
tumors in newborn mice [1]. Polyomaviruses are ubiqui-
tous in nature and are species-specific, including humans
(JC virus [JCV], BK virus), monkeys (simian virus 40
[SV40]), and mice (mouse polyoma virus) [2]. BKV was
first isolated in 1971 from the urine of a Sudanese renal
transplant patient with ureteric stenosis, whose initials
were B.K [3]. However, it was not until 1995 that the first
report of BK virus nephropathy (BKVN) in a renal trans-
plant recipient was published.
Genome
The BKV is a small (~45 nm) icosahedral, non-enveloped
double stranded DNA virus composed of 5000 base pairs
[2, 4]. The virus contains several domains: an early region
consisting of the replicative genes, large tumor antigen (T
antigen) and small tumor antigens (t antigen); a non-
coding control region (NCCR) adjacent to the early region
contains transcription factors for the early and late genes;
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and a late region encodes the viral capsid proteins (VP1,
VP2, VP3) [4, 5]. The BKV uses the host cell for replica-
tion and does not incorporate into the host genome.
There are four serologic BKV subtypes (I, II, III, and IV),
with predominance of type I in 70–80 %, followed by type
IV in 10–20 % [6]. The BKV genome also shares 75 %
homology to the JCV and 70 % homology to SV40 virus
[4]. JCV is more likely acquired at 10–14 years of age, with
higher incidence of JC viruria than BK viruria in the gen-
eral population at similar age range [4], and only a minor-
ity of cases (35 %) appear to co-activate BKV and JCV
simultaneously [7].
Epidemiology
The primary BKV infection often occurs around the
age of 3–4 years old [8], and once it is acquired, the
virus lies dormant in the renal tubular epithelial cells
[9]. BKV remains dormant in approximately 50 % of
native kidneys, localized to the renal medulla [7]. In
children under 10 years of age, the seroprevalence is
about 50 % [10]; and, by adulthood, this increases to
about 60–80 % [11]. Asymptomatic viruria occurs in
both healthy and immunocompromised patients [12],
with occurrence of < 5 % in the healthy population and
about 60 % in immunocompromised patients [10]. For
example, immunocompromised HIV positive patients
with lower CD4 cell counts are known to have a higher
prevalence of BK viruria [13].
Although BK viruria in most cases is not associated
with nephropathy or hemorrhagic cystitis, certain pop-
ulations have an increased risk of having BK viruria
progress to viremia and subsequently develop BKVN.
BKVN is the histological evidence of BKV-mediated
tubulo-interstitial inflammation, which may eventually
lead to renal failure.
In renal transplant patients, approximately 80 % of
renal transplant recipients develop BK viruria [5], and
5–10 % of those go on to develop BKVN within a year
of transplant [14], with loss of allograft function in
about 50 % of the cases. In bone marrow transplant re-
cipients, BKV-associated hemorrhagic cystitis is usually
seen two to three weeks after transplant in 5–60 % of
bone marrow transplant (BMT) recipients [4, 15].
Based on several case reports, BKVN may also affect
the native kidneys of lung [16], stem cell [17–23],
cardiac [17, 24–27] and solitary pancreas transplant
recipients.
BKV reactivation with asymptomatic viruria also occurs
in non-transplant patients on immunosuppression. The
prevalence of BK viruria was 22 and 55 % in adult patients
with multiple sclerosis [28] who received Natalizumab (an
α4-integrin monoclonal antibody (mAb)) and those with
inflammatory bowel disease [29] some of whom received
Infliximab (an anti-tumor necrosis factor alpha (TNFα)
chimeric mAb) and Adalimumab (anti-TNFα human
mAb), respectively. Children with idiopathic nephrotic
syndrome who were treated with Rituximab (an anti-
CD20 (B-cell) chimeric mAb), on 6-month follow-up
were noted to have 63 and 36 % of BK viruria and
viremia, respectively [30]. However, the true prevalence
of BKV in non-transplant patients may still be underes-
timated because this virus is not routinely screened in
this population.
Pathogenesis
The precise mechanism of BKV transmission has yet to
be determined; however, various routes have been im-
plicated, such as: fecal-oral, respiratory, and organ
transplantation [5]. Once acquired, the mechanism of
dormant virus reactivation in certain patients is also
not well known. It is thought to be stimulated by mul-
tiple predisposing factors related to the host immunity,
viral load, allogeneic immune response (graft rejection
or anti-lymphocyte antibodies) and inflammation (tis-
sue injury, leukocyte infiltration, and the release of pro-
inflammatory cytokines). Pre-existing damage to the
kidney might be a contributing factor to invasive virus
replication [31]. BKV reactivation may lead to progres-
sive infection and renal tubular epithelial cell lysis. If
the host’s immune system cannot mount BKV-specific
immunity due to immunosuppressive medications, then
renal dysfunction may ensue. One would assume that
damage ensued by SLE nephritis has the appropriate
milieu for BKV replication, but not enough data is
available to clearly state whether this is a direct risk fac-
tor for BKVN development.
Clinical manifestations of BKV infection
Genitourinary involvement
BK virus has tropism for the uroepithelial cells of the
genitourinary tract. It is associated with a variety of
complications in immunocompromised hosts, including:
hemorrhagic cystitis, BKVN, and ureteral stenosis. The
clinical presentation of BKVN is nonspecific with varying
degrees of renal failure without fever, leukocytosis,
hematuria or proteinuria. Often times the progression to
BKVN occurs without clinical signs and symptoms, except
for a rising serum creatinine over a period of one week.
BKVN is usually preceded by the virus presence in the
urine and subsequently in the plasma. BKV infection and
rising creatinine can also be confused with graft rejection
or other complications in renal and bone marrow trans-
plant recipients, which poses a complex issue regarding
therapy and management. Ureteral stenosis can present
with urinary obstruction and elevated serum creatinine
levels without symptoms of pain or discomfort since the
transplanted kidney is deinnervated. Hemorrhagic cystitis
in bone marrow transplant patients usually develops
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within two months of transplant and is presented with
hematuria, dysuria, urgency, frequency, or suprapubic
pain. With severe bleeding and clot formation, complica-
tions of urinary tract obstruction and renal failure may
occur [2].
Other organ involvement
A few case reports have commented on the association
of BKV infection in other non-renal organs, such as the
lungs, eyes, liver, brain and tonsils [2, 31–33]. Goudsmit
et al. [33] found BK viral DNA in the tonsils of children
with recurrent attacks of upper respiratory infection,
and Sundsjford et al. [34] found it in 2 of 201 nasopha-
ryngeal aspirate specimens; however, in both groups, no
infectious particles were isolated. Interstitial pneumon-
itis has been reported in at least two acquired immune
deficiency syndrome (AIDS) patients, one of whom pro-
gressed to acute respiratory distress syndrome and sub-
sequent fatality [35]. Another patient with AIDS, who
presented with subacute visual deterioration and neuro-
logic symptoms, was found to have BKV associated bilat-
eral multifocal retinitis, which was detected by standard
polymerase chain reaction (PCR) technique [36]. One
case report mentions association between BKV and
transaminitis in patients who were excreting the virus in
the urine; however, no liver pathology report confirming
this association have been published [37]. BK virus de-
tection in brain tissue by PCR has been demonstrated in
20 to 100 % of non-HIV immunosuppressed patients
with PML due to JCV [32]. Brain tissue for positive BKV
DNA using PCR has been reported in 2 of 13 HIV in-
fected patients who had progressive multifocal leukoen-
cephalopathy (PML) and 1 of 16 HIV-infected patients
who did not have PML [38]. However, low viral copy
loads that are undetectable by PCR may give false nega-
tive results.
Thus, these reports raise the question of BKV tissue
tropism, and how it becomes localized to the genitouri-
nary tract when other organs may be the primary site of
infection. These secondary sites of possible BKV infec-
tions also raises an important question of BKV associ-
ation in SLE, which is a multisystem autoimmune
disorder that can also affect the kidneys, brain, eyes,
liver, lungs and other organ systems. Since BKV is not
routinely assessed in all SLE patients, there is limited
data on the association of BKV and its involvement in
these other systems.
Diagnosis
Both qualitative and quantitative assessments for BKV
are available for diagnosis and management. Since
viruria often precedes viremia by several weeks, urine
cytology was first utilized to detect the presence of epi-
thelial cells containing BK viral inclusions which were
called “decoy cells”. Decoy cells are a morphological
marker for BKV replication. Detection of decoy cells has
a positive predictive value (PPV) of 27 % to indicate
BKVN and negative predictive value (NPV) of 100 %
[39]. However, the presence of decoy cells does not dis-
criminate between lower urinary tract versus a renal par-
enchymal infection.
A more specific test to quantify the BK viral load from
the urine and blood is via PCR. If the urinary BK virus
PCR is negative, then it is more sensitive for excluding
BKV as a cause of disease. A positive serum BK virus PCR
has a PPV of 50–85 % for BKVN and a NPV of 100 % [14,
39]. Based on the transplant literature, when the urine
BKV DNA >1 × 107 copies/ml and/or plasma BKV DNA >
1 × 104 copies/ml, a diagnosis of “presumptive BKVN” is
made, even in the absence of demonstrable BKV replica-
tion in renal biopsies [40]. However, there is no estab-
lished cutoff value for the level of viruria and viremia that
is associated with BKVN in non-renal transplant patients.
A renal biopsy, to identify the typical intranuclear
viral inclusion bodies in the renal tubular epithelial
cells, remains the gold standard for BKVN diagnosis
(see Fig. 1). However, even the renal biopsy can have
false negatives of up to 30 % due to the focality of the
BA
Fig. 1 A native renal biopsy with multiple intranuclear BK viral inclusions (a) and positive staining for SV40 T antigen (b) in the tubular epithelial
cells (identified by the arrows). There is also extensive interstitial fibrosis and tubular atrophy, along with prominence of inflammatory cells in the
interstitium and tubular cells
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BKV in the renal tissue [2, 41]. A positive immunohis-
tochemistry staining for SV40 T-antigen is pathogno-
monic for BKVN (see Fig. 1). An electron microscopy
shows polyomaviruses in the nuclei as crystalloid
particles [42].
BK virus and non-SLE immunocompromised patients
From the renal transplant literature, no single immuno-
suppressive agent definitively stands out as the culprit
associated with BKV infection. The medications in
transplant used most frequently include tacrolimus,
mycophenolic acid (MMF), and cyclosporine, all of
which inhibit cellular immunity thus affect T cell func-
tion and proliferation. Mengel et al. [43] showed that
higher tacrolimus (FK) trough levels (>8 ng/ml) or
MMF doses >1 g/day were associated with higher rates
of BKV reactivation. Brennan [44] also reported higher BK
viruria and viremia in the combination of FK-MMF (46 %)
compared to the Cyclosporine-MMF (13 %) (P = 0.005). A
retrospective study by Patel et al. [45] showed a higher in-
cidence of developing viral and fungal infections in renal
transplant patients who had received Rituximab compared
to the no Rituximab group. BK viremia was present in
27 % versus 13 % in the Rituximab and no Rituximab
groups, respectively (p = 0.011). It is plausible that Rituxi-
mab has long term effects on B-cell depletion and may
decrease viral-specific IgG, and therefore, may hinder BK
virus specific T-cell response [45]. Common medications
used to treat some SLE patients may also include steroids,
cyclophosphamide, MMF, Belimumab (anti-B lympho-
cyte stimulator) and Rituximab. MMF may be used to
treat SLE nephritis, but may be given at higher doses
than renal transplant patients (3000 mg/day compared
to 2000 mg/day).
In 2009, Lonergan et al. [28] presented the first report
of BKV reactivation in multiple sclerosis (MS) patients
being treated with Natalizumab. This prospective study
was conducted after MS patients were observed to have
PML with Natalizumab. The group detected BK viruria
in 8.3 % (3 of 36) prior to treatment and reactivation in
22.2 % (12 of 54). A longitudinal study by Delbue et al
[30] reported 63 % (7 of 11) and 36 % (4 of 11) of BK
viruria and viremia, respectively, at 6 month follow-up
in children with idiopathic nephrotic syndrome who
were treated with Rituximab,. BK viruria was detected in
3 of 11 patients before Rituximab, and only one had per-
sistent viruria.
BK virus in SLE
Systemic lupus erythematosus is an autoimmune dis-
order that can affect multiple organ systems, with up to
80 % of children presenting with renal involvement [46].
The disease manifests in childhood or adulthood, with
higher female preponderance. The exact etiology of SLE
is still unknown, but the pathogenesis of SLE includes
the loss of tolerance to self-antigens and the formation
of pathogenic antibodies directed against nuclear con-
stituents (antinuclear antibodies (ANA), anti-double
stranded DNA (dsDNA), anti-smith, ribonucleoprotein
(RNP), SSA (anti-Ro), SSB (anti-La) and anti-histone) as
well as complement mediated tissue destruction.
Since the 1980s, BKV infection was implicated in the
pathogenesis of triggering SLE based on animal models.
The development of anti-dsDNA appears to occur ex-
clusively in SLE or Mixed Connective Tissue Disease
whereas autoantibodies to histones are found in SLE,
drug induced SLE and rheumatoid arthritis. Flaegstad
et al. [47] demonstrated the production of antibodies to
host polynucleosomes and histones in BKV inoculated
rabbits. Moens et al. [48] demonstrated anti-dsDNA
and anti-histone antibody production in the presence of
a BKV T-antigen and host DNA complex in mice.
Fenton et al. [49] demonstrated the affinity of nucleosome-
T-antigen complexes for glomerular collagen IV and
laminin by surface plasmon resonance in human renal
biopsies from patients with SLE nephritis. The electron
dense structures in the biopsies (along glomerular ca-
pillary membranes and within mesangial matrix) con-
tained T-antigen, DNA and histones, which suggested
that the extra-cellular chromatin may originate from
polyomavirus infected cells in human kidneys. Hence,
the release of these complexes may induce autoimmun-
ity and be targeted by the induced pathogenic autoanti-
bodies. Rekvig et al. [50] showed evidence for BKV
reactivation in SLE patients by the simultaneous pres-
ence of BK viral DNA sequences in urine and anti-T-
antigen antibodies in serum samples. The patients who
had persistent viruria had higher titers for anti-T-
antigen antibody and anti-DNA antibody titers.
However, the most current theory of pathogenesis is
driven by the dysregulated clearance of apoptotic cells
and development of autoantibodies via the process of
“NETosis”. During NETosis, a specialized form of neu-
trophil cell death, the neutrophils extrude neutrophil
extracellular traps (NETs). The NETs are composed of
fibrillary networks composed of DNA, citrullinated his-
tones, and granule peptides (neutrophil elastase, myelo-
peroxidase, and cathepsin G), which serve to entrap
bacteria, viruses, fungi and parasites [51]. In SLE, there
is an excessive activity of NETosis and impaired clear-
ance of NETs, which results in an increased load of
nuclear autoantigens and an increased antigenic and
immunogenic potential [51]. Whether the presence of
BK virus in the renal tissue of SLE nephritis patients
implies that it is the cause of the renal symptoms or is
a bystander is to still be determined. Hence, although
causality of BKV and SLE has not been determined, an
association may still exist.
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There is significant correlation between the presence
of BKV and the development of SLE. A first study by
Taguchi et al. [52] first reported the isolation of BKV
from the urine of a patient with SLE. They were able to
demonstrate in two SLE patients the high serum
antibody titers against BK virus (1:40 to 1:1280) by
measuring cytopathic effect, the presence of urine decoy
cells, and demonstrated the presence of BKV antigen by
indirect immunofluorescent technique.
Since then, the prevalence of BKV viruria in SLE pa-
tients (see Table 1) has been reported at 16 % in SLE
and 0 % in matched healthy controls. About 26 % of
those patients continued to have persistent or recurrent
BK viruria at 1–3 years follow-up [34]. Bendiksen et al.
[53] showed that the BKV VP1 sequence was mainly of
one strain type (MM) in both SLE patients and immuno-
competent pregnant women in Norway. Different urine
samples from the same patients over one year were pre-
dominantly stable, which suggested that reactivation of
the viruses rather than recurrent or re-infections of pa-
tients with SLE was occurring. The mutation differences
in VP1 sequences in this group were silent, with only a
few missense mutations with amino acid substitutions.
Moreover, the urine samples of the SLE patients did not
possess JCV strains with a unique VP1 genotype, and
only three individuals of 21 SLE patients had the pres-
ence of both BKV and JCV in the urine.
Colla et al. [54] reported BKV viremia in 15 % and BKV
viruria in 32 % of adult SLE nephritis patients. The me-
dian number of genome copies/mL was 1.6 × 102 in the
blood and 1.6 × 104 in the urine via PCR. Lu et al. [55] re-
ported BKV viruria of 71.6 % vs 18.6 % in adult SLE and
control patients, with a log of 4.74 vs 1.08 (urine BKV
DNA copies/ml), respectively.
However, these studies did not find significant difference
between BKV DNA positive and negative SLE patients in
terms of SLE disease activity index (SLEDAI) score, pres-
ence of anti-dsDNA antibodies, CD4+/CD8+ ratio, and
therapy. Interestingly, patients with positive BKV viruria
exhibited a higher incidence of thrombocytopenia and
higher complement C3 levels [55]. Rainthavorn et al. [56]
reported that the prevalence of JCV and BKV reactivation
was higher in pediatric SLE patients that in the general
population. The study reported asymptomatic BKV viruria
in 32 % of children with non-active SLE. This study also
did not demonstrate a significant difference in the clinical
characteristics (including age, hemoglobin, white blood
cell count, platelet count, serum creatinine, complement
3, and frequency of pyuria or hematuria) among the BK
viruria positive and negative groups. Additionally, Poloni
et al. [57] reported a 17 year old female with lupus
nephritis who was noted to have urinary decoy cells iden-
tified by bright field microscopy and BK viruria was
confirmed by PCR (556 billion copies/ml). Umeda et al.
[58] recently reported a 22 year old Japanese female
with SLE who developed BKV-related hemorrhagic
cystitis and hemophagocytic syndrome during her SLE
flare treatment with immunosuppressive therapy, which
consisted of methylprednisolone, calcineurin inhibitors
(tacrolimus and cyclosporine), intravenous immuno-
globulin and intravenous cyclophosphamide. The ab-
dominal computed tomography showed thickened
bladder, urine cytology showed decoy cells, and BK vir-
uria was detected by PCR. The BK virus infection was
also confirmed in the bone marrow by the presence of
SV40-positive cells. With modification of the immuno-
suppressive therapy, BK viruria disappeared and both
hemorrhagic cystitis and hemophagocytic syndrome
resolved.
It is also important to note that the method of detec-
tion for BK viruria and/or viremia was different in all of
the above-mentioned studies. It is possible that the
sensitivity and specificity for BKV detection may have
been impacted based on the region of BK viral genome
amplification used for PCR and the type of PCR method
employed (nested vs semi-quantitative versus real-time).
Thus, with no standardized testing method for BK virus
across centers, inter-laboratory and inter-study variabil-
ity will limit comparisons and hamper identification of
threshold cut off values. Also, only two of these studies
had children in their inclusion criteria. The healthy
matched control in Colla et al. study may have impacted
the prevalence of BK infection since a significant num-
ber of control patients were healthcare workers.
BK virus and immunosuppression in SLE
Bacterial, viral, fungal and parasitic infections are a
major cause of morbidity and mortality in SLE patients.
Respiratory (sinusitis, pharyngitis, bronchitis, pneumo-
nia) and urinary tract infections are the most commonly
involved sites [59]. One of three SLE patients die due to
infection related complications; about 32 % SLE outpa-
tients develop infections over two years; and sepsis can
cause lupus nephritis to progress to end-stage renal
disease [60].
The alteration of the innate and acquired immune
systems in SLE patients increases the susceptibility to
infection and this is exacerbated by the use of immuno-
suppressive medications (see Table 2); which affect both
humoral and/or cellular immunity. Since an intact cel-
lular immune response is required to clear viral infec-
tions, an impeded cellular immune response to elevated
viral loads might contribute to the occurrence of BKVN
[61]. Moreover, the current era of immunosuppressive
therapy is now utilizing biologics at a higher frequency
than in the past. Biologics may alter humoral immunity,
cellular immunity and cytokine response, however, the
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long term effects of these drugs on the immune response
is still unclear. Although long-term data is lacking, infec-
tion is still a major immediate concern.
In SLE patients, the increased risk that immunosuppres-
sive agent(s) contribute to the risk of BKV infection or
reactivations is not known. Steroids and cyclophosphamide
are associated with a strong risk for infection [62],
while antimalarials may have a protective role [63]. Use
of biologic therapeutic agents that have been reported
in SLE patients include: Rituximab, Belimumab, and









Method of Detection Prevalence
BK viruria (SLE vs
healthy controls)
BK viremia (SLE vs
healthy controls)
Case series [52] 2 Adults Cytopathic effect and Hemagglutinin in prototype




44 Adults PCR analysis of the NCCR region of BKV and JCV 16 % vs 0 % (BKV) Not performed
Study: (41/3) 11 % vs 21 %
(JCV)
Control: (82/6)










5 Adults Nested PCR analysis for BKV DNA 40 % vs 16 % Not performed
Study: (4/1) Target: VP1
Control:
(25/0)b
Primers: BKV-P1, BKV-P5, BKV-P2 Co-detection of BKV and JCV was
present 4 % vs 0 %
Cross-sectional study [54] 40 Adultsc Semi-quantitative BKV DNA PCR analysis
(serum and urine)
32 % vs 17.2 % 15 % vs 13.8 %
Study: (29/11) Target BKV: pBK 385
Matched
Control: 29d
Positive if BKV PCR >1000 copies/ml
(viruria and viremia)
Simultaneous BK viruria and viremia
10 % vs 3.4 %
Cross-sectional study [49] 7 Adults Co-localization of anti-dsDNA and anti-T-antigen to
glomeruli by immune electron microscopy




Cross-sectional study [55] 95 Children and
Adults
Quantitative-real time BKV DNA PCR analysis 71.6 % vs 18.6 % Not performed
Study: 95 Target BKV: viral capsid protein (VP1)
Healthy
Control: 32
Positive if BKV PCR >50,000 copies/ml (viruria)
Cross-sectional study [56] 50 Children Nested PCR analysis for BKV DNA BKV: 32 % Not performed
Study: (41/9) Primers: JC/BK_433F, JC/BK_4390F JCV: 16 %
No control Co-detection of BKV and JCV was not
present
Case Report [57] 1 Female
Adolescent
Decoy cells in bright field microscopy Present with 556
billion copies/ml
BKV tested by quantitative PCR
Case Report [58] 1 Female Adult Urine cytology with decoy cells Not performed Not performed
Urine - qualitative PCR for BKV
Bone marrow – Positive SV40 stained cells
JCV JC virus, BKV BK virus, NCCR Noncoding control region, PCR Polymerase chain reaction, PYV Polyoma virus
a4 subjects were rheumatoid arthritis patients
bOnly those with SLE nephritis
cAll control subjects were pregnant women
d11 subjects were health care workers
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Table 2 Infections associated with immune-modulatory drugs used in SLE
Immuno-modulatory
Drugs [References]
Mechanism of Action Immune Target Viral Infections Bacterial Infections Fungal
Infections
Glucocorticoids
[60, 62, 64, 71]















MMF [62, 64–66, 73] Inhibition of IMPDH/de-novo purine
synthesis inhibitor











Chimeric human-mouse IgG1 anti-CD20
monoclonal antibody
B cells BK virus E.coli Aspergillus
CMV Mycobacteria Candida
EBV P. aeruginosa Nonaspergillus
mould
Enterovirus S. aures PCP
HSV S. typhii Tinea corpis
Hepatitis B & C Shigella






Belimumab [75] Human IgG1 antibody that binds to soluble
B-lymphocyte stimulator (BLyS or BAFF)





















MMF Mycophenolic acid, VZV Varicella zoster virus, CMV Cytomegalovirus, HSV Herpes simplex virus, EBV Ebstein-Barr virus, VZV Varicella zoster virus, RSV
Respiratory syncytial virus, UTI Urinary tract infection, PCP Pneumocystis carinii pneumonia, URI Upper respiratory infection
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Abatacept (anti-CTLA4 Ig). Rituximab, used for auto-
immune cytopenias associated with SLE, and Beli-
mumab block B cell activation. Abatacept, used in
patients with arthritis and lupus, modulates co-
stimulation of T-cells by antigen presenting cells. It is
important to note that the patients in Colla et al. and
Lu et al. studies had not received any biologics for ther-
apy. The medications reported in their studies included:
methylprednisolone, prednisone, cyclophosphamide, intra-
venous immunoglobulin (IVIG), azathioprine, cyclospor-
ine, or MMF. Therefore, it is not known if biologics are
more immunosuppressive and/or pose a higher risk for
BKV reactivation in SLE patients. Currently, BKV infec-
tion has been reported in SLE patients on Rituximab. The
association of BKV infection with other medications listed
in Table 2 is yet to be revealed. Since routine use of these
biologics in SLE has been more recent, the long-term
infectious profile of these drugs is uncertain and requires
monitoring. Furthermore biologics may be used concomi-
tantly with steroids and more traditional immunosuppres-
sive agents leading to multiple medications hampering the
immune response by different mechanisms. It is difficult
to ascertain to what degree of cellular or humoral impair-
ment will lead to activation of BKV if multiple immune
pathways are dysregulated simultaneously.
Prognosis
BK virus nephropathy is an irreversible condition that can
lead to renal failure. Since BKVN occurs in up to 10 % of
renal transplant recipients, with half losing their allograft,
screening for BK virus infection is part of routine care in a
renal transplant patient. However, this is not the case for
other non-renal transplant or immunosuppressed patients.
Increase in serum creatinine as a marker for renal dysfunc-
tion may be too late in the disease process since the glom-
erular filtration rate has already decreased by half by that
time. Thus, although a firm recommendation to obtain rou-
tine BKV screening in all SLE patients cannot be made
from this review, clinicians should consider BKV screening
as clinically indicated, especially in the setting of protein-
uria, hematuria, and/or rise in serum creatinine. A simple
test for BKV may change management and tailoring of
therapies for such vulnerable patients. Further research is
needed to determine the formal recommendations for BKV
screening and monitoring in this patient population.
Treatment
Once there is detection of BK viruria and viremia, the
treatment strategy for BKV infection is not uniform and
will need further investigation. Extrapolation from the
renal transplant literature reveals that an acceptable
treatment plan involves reducing immunosuppressive
medications and monitoring serum creatinine and BKV
load periodically. Ancillary therapies such as cidofovir
[76], leflunomide [77, 78], quinolones [79, 80] and IVIG
[81, 82] have been employed, but they have not proven
to be more efficacious than screening and reduction of
immunosuppressive therapy in renal transplant recipi-
ents (see Table 3). The reduction of immunosuppression
in SLE patients in order to allow better host clearance of
the virus could potentially have deleterious effects on
their underling autoimmune disease and is therefore a
limited option and requires further consideration.
Conclusions
It is important to delineate the interaction between BKV,
the altered immune system and the affected kidneys of SLE
patients to fully understand how to effectively diagnose and
manage BKV infection in these patients. This information
may impact immunosuppression therapy choices, which
may also affect the control of the autoimmune disease. At
this time, more information is still needed about the
Table 3 Treatment Options for BK virus infection from the renal transplant literature
Drug [Reference] Mechanism of action Dose Adverse effect
Cidofovir [76] Synthetic purine nucleotide analogue of cytosine viral
DNA polymerase inhibitor





De novo pyrimidine synthesis inhibitor Loading dose of 100 mg for 5 days, then




Target blood level of 50 to 100 ug/mL
Fluoroquinolones
[79, 80]
DNA gyrase inhibitor (interferes with T antigen
helicase activity in BKV)
Levofloxacin 500 mg/day x 1 month Tendinitis
Ciprofloxacin 250 mg BID daily x 1 month
IVIG [81, 82] Direct neutralizing activity and other
immune-modulatory effects
Variable doses of 0.2 to 2.0 g/kg: Osmotic
nephropathy
1) 600 mg/kg every 4–6 weeks Headache
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prevalence and incidence of BKV infection in SLE, espe-
cially children, with and without nephritis. More studies are
needed to establish the threshold cut-off values for signifi-
cant BK viral load and risk for BKVN in non-transplant
immunocompromised patients. Furthermore, randomized
controlled trails and algorithms are needed to identify the
best treatment strategies to treat at-risk children and adults
who acquire BKV infection, especially in the non-renal
transplant setting. In summary, by understanding the rela-
tionship between BKV and the altered immune system in
SLE, we may be able to extrapolate this information to
other at-risk populations to impact proper surveillance,
diagnosis and treatment.
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